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1MANUSCRIPT1
Title of the article: Improving Medication Safety and Diabetes Management in Hong Kong – A2
Multi-disciplinary Approach3
4
ABSTRACT5
Aim: To characterise drug-related problems (DRPs) among patients with diabetes in Hong Kong6
and their clinical significance and to explore pharmacists’ role in the multi-disciplinary diabetes7
management team by evaluating the outcome of their clinical interventions.8
9
Methods: An observational study was conducted at the Diabetes Clinic of a local public hospital10
from October 2012 to March 2014. Following weekly screening, selected high-risk patients were11
interviewed by a pharmacist prior to doctors’ consultations for medication reconciliation and12
review. DRPs were identified and documented by the pharmacists, who presented clinical13
recommendations to doctors to optimise patients’ drug regimens and resolve or prevent potential14
DRPs.15
16
Results: A total of 522 patients were analysed and 417 DRPs were identified. The incidence of17
patients with DRPs was 62.8% with the mean number of DRPs per patient being 0.9±0.6. The18
most common DRP categories were related to dosing (43.9%), drug choice (17.3%) and non-19
allergic adverse reactions (15.6%). Drugs most frequently involved targeted the endocrine and20
cardiovascular system (CVS). The majority (71.9%) of DRPs were of moderate clinical21
significance and 28.1% were considered minor problems. DRPs were totally solved by doctors’22
acceptance of pharmacists’ recommendations (50.1%), partially solved (11.0%) or received23
acknowledgement from doctors (5.5%).24
25
Conclusions: Pharmacists, in collaboration with the multi-disciplinary team, demonstrated26
positive impact by identifying, resolving and preventing DRPs in patients with diabetes. Further27
plans for sustaining a pharmacy service in the Diabetes Clinic would enable further studies to28
explore pharmacists’ long-term impact on improving patients’ clinical outcomes in diabetes29
management.30
2New knowledge added by this study:31
Studies have demonstrated pharmacists’ important contribution to the identification, resolution32
and prevention of drug-related problems through medication reconciliation and review. Most of33
the identified problems were related to dosing with moderate clinical significance according to34
Dean and Barber’s validated scale for scoring medication errors. Over half of pharmacists’35
clinical interventions were accepted or acknowledged by doctors to improve medication36
management.37
38
Implications for clinical practice or policy:39
Collaboration between pharmacists and other healthcare professionals is valuable for the40
improvement of medication safety in the management of diabetes.41
3TEXT42
43
Introduction44
Diabetes mellitus (DM) is a prevalent chronic disease worldwide.1 Patients with diabetes often45
require complex medication regimens and are likely to develop multiple irreversible complications,46
which significantly worsen their quality of life.2 Effective DM management requires collaboration47
among healthcare professionals (HCPs) in a multi-disciplinary diabetes management team (DMT),48
where pharmacists are well positioned to optimise pharmacological treatment, educate patients on49
diabetes management and promote medication adherence.350
51
Pharmacists’ major roles in DMT is to conduct medication reconciliation (MR) and medication52
review. MR is the process of comparing patient’s prescriptions with all their usual medications53
and to identify the most complete and updated medication history.4 Medication review aims to54
check patients’ past medical and drug history, assess current prescriptions and ascertain their drug55
knowledge and adherence.5 Through these processes, pharmacists can effectively identify drug-56
related problems (DRPs), which are events or circumstances involving drug therapies that either57
actually or potentially interfere with optimum health outcomes of specific patients.6, 7 People with58
chronic diseases usually require polypharmacy (concurrent use of multiple medications), from59
which DRPs can easily arise.8, 9 These DRPs might be overlooked by prescribers and could60
interfere with diabetes management. From several overseas studies, pharmacists have61
implemented timely interventions to resolve or prevent DRPs by offering recommendations to62
prescribers, with an acceptance rate over 60%.10-1363
64
4The positive impact of pharmacists on improving diabetes management or its comorbidities has65
also been recognised by interventional and controlled observational studies worldwide, which66
demonstrated greater overall improvement in glycosylated haemoglobin (HbA1c), fasting plasma67
glucose (FPG), blood pressure (BP), most cholesterol components, renal outcomes and medication68
adherence in patients who received pharmacist-led diabetes services compared to standard care.12,69
14-30 However, only a few studies were conducted in Hong Kong (HK).16, 29 In a view of inadequate70
available data and potential for expansion of local pharmacy services, more studies are required to71
investigate the development of future sustainable diabetes service provision by pharmacists.72
73
Our study aimed to characterise DRPs among Chinese diabetic outpatients, define their clinical74
significance and outcomes of pharmacists’ interventions, thereby highlighting their contribution75
to the detection, resolution and prevention of DRPs for improving medication safety and diabetes76
management.77
78
Materials and Methods79
Study design and setting80
An observational study was conducted weekly, in the Diabetes Clinic at Queen Mary Hospital81
(QMH) from October 2012 till March 2014. The study protocol was approved by the Institutional82
Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.83
84
Inclusion/Exclusion criteria85
Patients were included if they were at “high risk” due to their multiple disease state and complex86
drug regimen fulfilling each of the following criteria:87
5 Aged ≥65 years 88 
 Taking five or more medications including all routes of administration, or over the counter89
(OTC) medications (regular or as needed)90
 Taking medications with a low therapeutic index or require monitoring91
 Attending multiple specialist clinics92
Nursing home residents were excluded due to their relatively low risk for non-adherence and DRPs,93
compared to community dwelling elderly patients.94
95
Procedure and materials96
Day before the clinic, two researchers screened the past medical history (PMH), previous97
consultation notes, current medications and latest laboratory results of Chinese adult patients98
attending the weekly clinic to select high-risk patients. Selected patient’s records were printed and99
prepared for quick reference during the medication interview. To facilitate the data collection, a100
memo was attached with the patient’s records to notify nurses for patient selection.101
102
Two pharmacists from QMH and one from University of Hong Kong (HKU) attended the clinic103
on alternate Wednesdays to compile a thorough medication history from selected patients and104
conduct medication review independently prior to doctors’ consultations. During review, the105
pharmacists also recorded medications not shown in Clinical Management System (CMS),106
including drugs prescribed by general practitioners (GPs), OTC products, vitamins and herbal107
supplements.108
6A MR form (Appendix 1) was then completed by the pharmacists, documenting the identified109
DRPs and formulating the intervention proposal. The MR forms were collected following doctors’110
consultations either on the same day or within the next few days.111
Pharmacists Intervention112
It included:113
 Reviewing patient’s drug regimen and making recommendations to doctors for adjustment.114
 Informing doctors regarding most updated drug list after MR.115
 Suggesting need for further investigating patient’s condition.116
 Providing drug education to patients and caregivers.117
 Reinforcing patient’s drug compliance.118
 Suggesting lifestyle modification such as dietary control.119
120
Identifying DRP’s121
From the completed MR forms, DRPs were identified and pharmacists’ recommendations were122
collected for analysis, CMS was checked for outcome of intervention.123
124
Data Collection125
Demographic data such as age, gender, drug allergy status, number of regular medications obtained126
from HA clinics (Table 1) and some latest laboratory values, including HbA1c, FPG, and lipids127
were retrieved from CMS (Appendix 2). Additional information included patients’ care provider128
in terms of medication, drug storage methods, smoking status, drinking habits, vaccination record129
and latest readings from self-monitoring of blood glucose (SMBG).130
131
7Data analysis132
Demographic data are tabulated as frequency and percentage using Microsoft Excel 2010. Primary133
outcomes included the frequency and categories of DRPs, drug classes involved, clinical134
significance of DRPs and outcome of pharmacists’ interventions. The incidence of DRPs was also135
calculated as the percentage of patients with at least one DRP.136
137
Definition and classification of DRPs138
Using the Pharmaceutical Care Network Europe (PCNE) classification system for DRPs V5.01,139
DRPs were categorised into “adverse reactions”, “drug choice problem”, “dosing problem”, “drug140
use problem”, “interactions” and “others”.7 This is an established system that has been revised141
several times with tested validity and reproducibility11, 31 and has been used in many studies.9, 32 33142
When a single drug was associated with more than one possible DRP category, the one that best143
described the clinical scenario was chosen. Drugs involved in DRPs were categorised according144
to British National Formulary classification.34145
146
The clinical significance of DRPs was assessed to determine their actual or potential consequences147
on patients’ health outcomes. Using a validated scale,35 four independent reviewers (two148
pharmacists and two doctors) scored the severity of each DRP from zero (without potential effects149
on the patient) to 10 (lead to a fatal event). Mean scores below three indicated minor problems150
(very unlikely to cause adverse effects) while three to seven indicated moderate problems (likely151
to cause some adverse effects or interfere with therapeutic goals). DRPs scoring above seven were152
severe and could likely cause death or lasting impairment.153
154
8To evaluate prescribers’ acceptance levels, the outcome of pharmacists’ interventions were155
categorised into “not known”, “solved”, “partially solved” or “not solved” according to PCNE156
classification V5.01.7157
158
Results159
Patient demographics and characteristics160
Within the study period, a total of 652 patients were included based on the selection criteria, from161
which 526 (80.7% of 652) were interviewed and 522 (99.2% of 526) were analysed (Figure 1).162
163
The age of the 522 patients ranged from 65-91 (mean of 75.2±5.4 years). The number of regular164
HA medications taken ranged from 5-17 with a mean of 9±2.165
166
Incidence and classification of DRPs167
A total of 417 DRPs were identified. Among the 522 patients analysed, 328 patients had at least168
one DRP with the incidence of 62.8% and the mean number of DRPs per patient as 0.9±0.6. The169
most prevalent DRP category was related to dosing (n=183, 43.9%), followed by drug choice170
(n=72, 17.3%) and non-allergic adverse reaction (n=65, 15.6%). Each of these is sub-categorised171
in Table 2.172
173
Categories of drugs involved in DRPs174
The most common class of medication involved were those targeting the endocrine system with175
190 DRPs (45.6%) followed by cardiovascular system (CVS) with 159 (38.2 %) DRPs (Table 3).176
177
9Clinical significance of DRPs178
The average clinical severity scores assigned to DRPs ranged from 0.5-7.0 (Table 4). The majority179
of DRPs (n=300, 71.9%) were classified as moderate problems while remaining were all minor180
problems (n=117, 28.1%). No clinically severe DRP was identified.181
182
Outcome of pharmacists’ interventions183
As Table 5 shows, modifying drug regimens or reinforcing compliance by doctors or referral to184
pharmacists solved 209 (50.1%) DRPs. Forty-six (11.0%) DRPs were partially resolved by doctors185
adjusting prescriptions, although not to pharmacists’ recommendations. Sixty-two (14.9%) DRPs186
were not resolved due to patients’ reluctance to change prescriptions, absence of the need for187
resolution or due to some unknown reasons. Twenty-three (5.5%) DRPs had an unknown outcome188
because they were non-compliance issues that were not acknowledged by doctors.189
190
Discussion191
The incidence of patients with DRPs and the average number of DRPs per patient analysed were192
comparable to a Norwegian study (58.9% and 1.2 respectively)10 but considerably lower from four193
overseas studies (incidence of 80.7-90.5% and mean number of DRPs per patient between 1.9±1.2194
and 4.6±1.7).9, 11, 12, 36 Such discrepancies might be attributed to variations in patient selection195
criteria, data collection methods, pharmacists’ clinical experience, study durations and settings.9,196
36, 37197
198
The majority of DRPs were dosing problems, with “drug dose too low or dosage regime not199
frequent enough” being the largest sub-category. In contrast to the lower percentage (5.9-21.6%)200
10
in five overseas studies,9-12, 36 our high prevalence of dosing problems was in-line with a local201
study on medication incidents among hospital inpatients,38 mostly arising from self-adjustment of202
dosage or frequency, confusion about previous dose changes and dosage modification by GPs or203
doctors overseas. These highlight local pharmacists’ pivotal roles in conducting MR, reviewing204
drug dosages to ensure safety and efficacy, monitoring patients’ metabolic control regularly as205
well as reminding patients and/or their caregivers to maintain an updated medication list and206
follow the latest drug label instructions.207
208
Drug choice problem was the second most common DRP in the study. Nearly 17.3% of DRPs209
were issues surrounding drug choice, comparable to the findings of three overseas studies (9.1-210
30.2%)11, 12, 36 but deviating from others (18.2-22.5%).9, 10 The most common sub-category was211
“no drug prescribed but clear indication”, such as the omission of angiotensin-converting enzyme212
inhibitor/ angiotensin-receptor blocker (ACEI/ARB) in patients with microalbuminuria and213
patients’ reluctance to use insulin. Hence, pharmacists have a role in advising doctors to adhere to214
the latest treatment guidelines and educate patients about the treatment benefits of each drug215
class.39 Other causes of problems surrounding drug choice include drug duplication and changes216
in drug choices by GPs to prevent side effects, suggesting that some DRPs might have arisen from217
the lack of a common platform for sharing patient information between the public and private218
healthcare sectors. Pharmacists could make valuable contributions by establishing patients’ drug219
history through MR and from liaison with the different healthcare sectors.220
221
Adverse reactions were the third most common DRP (15.6%). The major types of “side effects222
suffered (non-allergic)” were insulin-induced hypoglycaemia, gastrointestinal disturbances and223
11
dizziness caused by anti-diabetic drugs, for which pharmacists recommended changes in drug224
choice or dosage. Adverse reactions could lead to other DRP categories,7 such as drug choice and225
drug use problems. This reflects pharmacists’ pivotal role in reviewing prescribed doses,226
suggesting dosage adjustments to doctors, monitoring for adverse effects and education on227
prevention of side effects (such as performing SMBG regularly to prevent hypoglycaemia).39228
Drug use issues were the fourth most common category with comparable prevalence (12.0%) to a229
Malaysian study9 but there is considerable variation among other studies (3.8-54.2%).10-12, 36230
Reasons for the sub-category of “drug not taken/administered at all” include financial issues for231
purchasing self-financed item (SFI) items, unawareness of indications, concern about side effects232
and confusion about previous regimen changes.40 In our study, pharmacists mainly intervened233
using direct patient counselling, recommending reinforcement of patient compliance to doctors or234
suggesting changes to drug regimens. Pharmacists could also work closely with other DMT235
members to educate patients about their disease and the most updated regimen, address drug cost236
concerns or side effects, and encourage patients to update their medication list and use dose237
administration aids (DAAs) like pill boxes.41238
239
The low prevalence of drug interactions (1%) was similar to that (0.6%) in a Danish study,36 but240
much higher percentages were found in three other studies (8.0-16.3%),9-11 possibly ascribed to241
differences in prescribing practice, references used to define drug interactions,9 and also because242
CMS could already detect a range of clinically significant interactions when doctors issued243
prescriptions. Nonetheless, system checking and prompts are not adequate to replace clinical244
judgment or recommendations of alternative regimens. “Others” included “insufficient awareness245
of health and diseases” (such as poor dietary control) and “inappropriate timing of administration”,246
12
but this category could also encompass therapy failure and inappropriate lifestyle choices, resulting247
in greater variation of prevalence from overseas studies (6.8-46.6%).9-11, 36 Pharmacists are ideally-248
positioned to advise patients on diabetic diet, smoking cessation, regular exercise and SMBG.21249
250
The drugs classes mostly implicated in DRPs were found to be for endocrine system (45.6%)251
followed by CVS (38.2 %). These findings were not surprising as insulins, oral anti-diabetic drugs,252
antihypertensives, antihyperlipidaemics, antiplatelets and ACEIs/ARBs are most commonly253
prescribed for managing diabetes, its comorbidities and complications.11, 39254
255
The majority of DRPs were classified as moderate problems. Among similar overseas studies, only256
one analysed the clinical significance of DRPs, in which 87% of DRPs had high or medium257
clinical/practical relevance.10 These findings could not be readily compared to the present study258
because of different assessment scales, potential variations in reviewers’ clinical experience35 and259
unknown relative proportions of cases with medium and high relevance.260
261
Over half of the DRPs were totally solved as doctors accepted pharmacists’ recommendations. The262
acceptance rate was somewhat similar to that observed in two overseas studies (60.2-62.7%).12, 13263
The physicians acknowledged the provision of service by pharmacists and were more aware of the264
written recommendations provided by pharmacists. In particular, the value of verbal265
communication between different HCPs in resolving or preventing DRPs has been recognised in266
earlier studies,10, 42-45 suggesting potential improvement in the acceptance rate if pharmacists had267
more time to hand over DRPs verbally to doctors.268
269
13
The outcome of pharmacists’ interventions could also be influenced by doctors’ clinical experience270
and familiarity with the new service. Doctors’ acceptance levels could have been underestimated271
since some of them might have neglected or missed written information from pharmacists. This272
highlights the importance of promoting pharmacists’ roles among doctors and keeping all273
participating doctors well-informed.274
275
Difficulties and limitations276
This pilot study allowed for an opportunity to assess the proportion of patients who may be seen277
by clinical pharmacists in a busy specialist outpatient clinic at a teaching hospital. Approximately278
10% of patients were chosen each week and not all eligible patients could be selected owing to279
time limitation. The volume of patients actually interviewed was further limited due to time280
constraint, patients’ absence or refusal. Local figures from the QMH Diabetes Clinic indicate that281
out of all patients attending the clinic, approximately 7-8% are deemed “high risk”, based on282
ongoing work and prioritisation of those taking 5 or more regular medications.283
Limited work space was another consideration. A designated area is required for conducting284
patient interviews and further arrangements could be made with the medical and nursing staff in285
Diabetes Clinic to access better space.286
287
This study only described the current situation of DRP’s without assessing the extent of288
implementation of intervention and their impact on patient health outcome. As the majority of289
patients did not bring their drugs and had no medication list available, the MR process was not290
always effective. Whilst a minority of patients could name their regular drugs, the majority relied291
on pharmacists’ investigation and prompts describing the colour, shape, package or indication of292
14
each drug. Due to potential for misinterpretation, DRP prevalence may be underestimated. One293
possible solution might be to show patients samples of commonly prescribed medications.294
Alternatively, selected patients could be telephoned in advance to remind them to bring along their295
medications, however this measure may not be sustainable. A multifaceted promotional campaign296
could be introduced to encourage patients to bring their regular medications. This has been shown297
to be effective in the emergency setting.46298
Although completed MR forms were presented to doctors after the interviews, some written299
information might have been missed, resulting in their lack of response to certain DRPs.300
Pharmacists should ideally hand over every DRP verbally to doctors, however this was not always301
possible due to time constraints and the great volume of patients. In the long run, it would be302
desirable for pharmacists to document DRPs and their recommendations in CMS, which would303
enhance visibility and allow doctors to input their response electronically for organised304
documentation and easy data retrieval.305
306
Future directions307
After this study, pharmacists have continued providing MR and medication review services in308
QMH Diabetes Clinic. They also have been collecting data about DRPs to plan for a sustainable309
service. Following a longer study period, patient and staff satisfaction surveys could be introduced310
and also control groups can be added in study for comparing the effectiveness of pharmacist’s311
intervention. This can further support the extension of hours of service and potentially the setup312
of similar pharmacy services to other hospitals and diabetic clinics in Hong Kong.313
314
315
15
Conclusions316
Approximately two-thirds of patients at Diabetes Clinic had at least one DRP. The most frequent317
categories of DRPs were related to dosing, drug choice and non-allergic adverse reaction. Drugs318
targeting the endocrine and CVS were most commonly involved. The majority of DRPs were of319
moderate clinical significance. Pharmacists’ interventions for over half the DRPs were accepted320
or acknowledged by prescribers. Through effective communication and collaboration within the321
multi-disciplinary healthcare team and pharmacists had a positive impact on identifying, resolving322
and preventing DRPs. Future plans for sustaining the diabetes service would enable more local323
research to enhance medication safety and optimise patients’ medication regimens in diabetes324
management.325
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Table 1. Demographics and characteristics of study population
Patient demographics n (%)
Age (Mean Age) 65 – 91 years (75.2±5.4 years)
Gender
Female 269 (51.5)
Male 253 (48.5)
Drug allergy status
No known drug allergy 448 (85.8)
Known drug allergy 74 (14.2)
On medications or supplements other than those prescribed by HA clinics
Yes 119 (22.8)
No 403 (77.2)
Care provider in terms of medications
Self 364 (69.7)
Family member 80 (15.3)
Domestic helper 26 (5.0)
Self and family 20 (3.8)
Family and domestic helper 5 (1.0)
Self and domestic helper 3 (0.6)
Community nurses 9 (1.7)
Not recorded 15 (2.9)
Method of storing medications
DAA* 340 (65.1)
Original dispensing bag 125 (24.0)
Others † 22 (4.2)
DAA and original dispensing bag 6 (1.1)
DAA and others 2 (0.4)
Original dispensing bag and others 3 (0.6)
Not recorded 24 (4.6)
Medications brought in with patient
None 428 (82.0)
Some of the medications 50 (9.6)
All of the medications 14 (2.7)
Not recorded 30 (5.7)
Medication list available on visit
Yes 39 (7.5)
No 431 (82.6)
Not recorded 52 (9.9)
Smoking status
Non-smoker 384 (73.6)
Ex-smoker 100 (19.2)
Current smoker 21 (4.0)
Not recorded 17 (3.2)
Drinking habit
23
Non-drinker 465 (89.1)
Light drinker 27(5.2)
Moderate drinker 2 (0.4)
Ex-drinker 5 (0.9)
Not recorded 23 (4.4)
Record of latest SMBG readings available
Yes ‡ 267 (51.1)
No or not recorded 255 (48.9)
Received pneumococcal vaccine within past 5 years
Yes 77 (14.7)
No 386 (74)
Not recorded or not sure 59 (11.3)
Received influenza vaccine for current year
Yes 164 (31.4)
No 302 (57.9)
Not recorded 56 (10.7)
Previous hepatitis B vaccine
Yes 8 (1.5)
No 434 (83.2)
Not recorded or not sure 80 (15.3)
DAA, dose administration aid; HA, Hospital Authority; SMBG, self-monitored blood glucose.
* Examples include pill boxes, monitored dosage systems and patients’ dispensing cabinets.
† Examples include film bottles and patients’ plastic bags or containers.
‡ Patients who did not bring their records but recalled some readings were excluded from “yes”.
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Table 2. Frequency and categories of DRPs
Category of DRPs n (%)
1. Adverse reactions
Side effect suffered (non-allergic) 65 (15.6)
2. Drug choice problem
Inappropriate drug 8 (1.9)
Inappropriate drug form 2 (0.5)
Inappropriate duplication of therapeutic group or active ingredient 18 (4.3)
Contraindication for drug 5 (1.2)
No clear indication for drug use 4 (1.0.)
No drug prescribed but clear indication 35 (8.4)
Subtotal 72 (17.3)
3. Dosing problem
Drug dose too low or dosage regime not frequent enough 97 (23.3)
Drug dose too high or dosage regime too frequent 69 (16.5)
Duration of treatment too long 17 (4.1)
Subtotal 183 (43.9)
4. Drug use problem
Drug not taken/administered at all 50 (12.0)
5. Interactions
Potential interaction 3 (0.7)
Manifest interaction 1 (0.2)
Subtotal 4 (1.0)
6. Others
Insufficient awareness of health and diseases (possibly leading to future problems) 33 (7.9)
Inappropriate timing of administration 2 (0.5)
Therapy failure 1 (0.2)
Patient dissatisfied with therapeutic outcome despite taking drugs correctly 7 (1.7)
Subtotal 43 (10.3)
Total number of DRPs 417 (100)
Incidence of patients with DRPs 328 (62.8)
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Table 3. Frequency and classes of medications involved in DRPs
Class of medications Number of DRPsinvolved (%) Examples
Cardiovascular system 159 (38.2) Aspirin, perindopril, losartan, valsartan, metoprolol tartrate, atenolol, labetalol, simvastatin, atorvastatin,amlodipine, isosorbide mononitrate, frusemide, hydrochlorothiazide, hydralazine, warfarin
Endocrine system
Insulins 133 (31.9) Regular insulin, isophane insulin, biphasic isophane insulin, insulin glargine
Anti-diabetic drugs 56 (13.5) Metformin, gliclazide, sitagliptin
Sex hormones 1 (0.2) Finasteride
Subtotal 190 (45.6)
Nutrition and blood 21 (5.0) Calcium carbonate, potassium chloride, darbepoietin alfa injection
Gastrointestinal system 14 (3.5) Pantoprazole, rabeprazole, famotidine, digestive enzymes
Obstetrics, gynaecology
and urinary tract
disorders
6 (1.4) Prazosin, terazosin, doxazosin
Respiratory system 5 (1.2) Theophylline, ipratropium, salbutamol, beclomethasone, loratadine
Malignant disease and
immunosuppression 3 (0.7) Azathioprine, prednisolone
Central nervous system 3 (0.7) Gabapentin, pregabalin, tramadol
Infections 1 (0.2) Isoniazid and rifampicin
Musculoskeletal and
joint diseases 5 (1.2) Allopurinol, colchicine
Skin 1 (0.2) Fluocinolone acetonide cream
Others 1 (0.2) Peritoneal dialysis fluid
Multiple drugs* 8(1.9)
Total 417(100)
DRP, drug-related problem. * In most of the cases the DRPs were related to poor drug compliance by the patient.
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Table 4. Frequency and categories of clinical severity scores assigned to DRPs
Severity category Averagescore n (%)
Minor
0.5 1 (0.2%)
1 12 (2.9%)
1.25 2 (0.5%)
1.5 10 (2.4%)
1.75 4 (1.0%)
2 33 (7.9%)
2.25 7 (1.7%)
2.5 30 (7.2%)
2.75 18 (4.3%)
Subtotal 117 (28.1%)
Moderate
3 45 (10.8%)
3.25 22 (5.3 %)
3.5 29 (7.0%)
3.75 16 (3.8%)
4 65 (15.6%)
4.25 8 (1.9%)
4.5 27 (6.5%)
4.75 7 (1.7%)
5 42 (10.1%)
5.25 5 (1.2%)
5.5 11 (2.6%)
5.75 2 (0.5%)
6 15 (3.6%)
6.5 1 (0.2%)
6.75 1 (0.2%)
7 4 (0.9%)
Subtotal 300 (71.9%)
Total number of DRPs 417 (100)
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Table 5. Outcome of pharmacists’ interventions
Outcome of pharmacists’
interventions n (%) Examples
Outcome of intervention
not known
77
(18.5)
 A patient took sitagliptin 50mg instead of 100mg daily claiming that doctor told her half a tablet would be
enough. Pharmacist asked the doctor to review but no record was made in CMS and doctor continued
prescribing 100mg daily.
Problem totally solved 209(50.1)
 A patient on perindopril, whose dose was increased in Nephrology clinic during last follow up, presented
with hyperkalaemia (serum potassium level: 5.7mmol/L). Pharmacist suspected the cause as the side
effect of ACEI. Physician agreed to cease drug until next follow up in Nephrology clinic.
Problem partially solved 46(11.0)
 A patient was prescribed with the following antidiabetic drugs by GP: metformin 500mg BD, sitagliptin
50mg OD and glimepiride 1mg OD. In view of patient’s renal function (serum creatinine increased from
193 umol/L to 213 umol/L), pharmacist suggested stopping metformin and changing sitagliptin to
linagliptin. Physician noted “strongly advised to stop metformin” in CMS, but made no comment on
changing sitagliptin.
Not solved
Lack of cooperation of
patient 5 (1.2)
 A T2DM patient had good adherence to four oral anti-diabetic drugs (metformin 1500mg BD, gliclazide
160mg BD, sitagliptin 100mg daily and acarbose 50mg TDS). The pharmacist explained that the
maximum doses of most drugs had already been reached, but the patient still refused admission, insulin
therapy or any additional medications. His latest HbA1c was 12.6% and FPG was 19.6mmol/L. The
doctor recorded the problem in CMS, explained health risks and advised patient to attend Emergency
Department if he feels unwell.
No need or possibility to
solve problem 35 (8.4)
 The pharmacist recorded that a patient would discuss with the doctor in Orthopaedics Clinic regarding
calcium carbonate 1000mg daily due to constipation. The doctor in Diabetes Clinic did not record the
problem in CMS and kept the current dosage.
For unknown reasons 22 (5.3)
 Frusemide dosage prescribed in Cardiology clinic was increased from 20mg BD to 40mg mane and 20mg
nocte by GP due to oedema. The doctor in Diabetes Clinic neither made a record nor changed the
prescription.
Subtotal 62(14.9)
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Others (Acknowledged by
doctor, no action taken) 23 (5.5)
 A patient who had coronary artery disease, self-adjusted the dosage of metoprolol tartrate from 25mg BD
to 25mg daily. The doctor recorded the problem but did not prescribe the drug (for follow up in
Cardiology clinic).
Total 417(100)
ACEI, Angiotensin-converting-enzyme inhibitor; BD, twice daily; CMS, Clinical Management System; DM, Diabetes Mellitus; FPG, fasting plasma
glucose; GP, general practitioner; HbA1c, glycosylated haemoglobin; mane, every morning; nocte, every night; OD, once daily; SFI, self-financed item;
T2DM, type 2 diabetes mellitus; TDS, three times daily.
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